vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and WYNDHAM HOTELS & RESORTS, INC. (WH). Click either name above to swap in a different company.
WYNDHAM HOTELS & RESORTS, INC. is the larger business by last-quarter revenue ($334.0M vs $180.9M, roughly 1.8× AVANOS MEDICAL, INC.). AVANOS MEDICAL, INC. runs the higher net margin — -0.7% vs -18.0%, a 17.2% gap on every dollar of revenue. On growth, AVANOS MEDICAL, INC. posted the faster year-over-year revenue change (0.7% vs -76.3%). WYNDHAM HOTELS & RESORTS, INC. produced more free cash flow last quarter ($168.0M vs $21.3M). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs -4.6%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Wyndham Hotels & Resorts, Inc., is an American hospitality company based in Parsippany, New Jersey, United States. It describes itself as the largest hotel franchisor in the world, with 9,100 locations.
AVNS vs WH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $334.0M |
| Net Profit | $-1.3M | $-60.0M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | — |
| Net Margin | -0.7% | -18.0% |
| Revenue YoY | 0.7% | -76.3% |
| Net Profit YoY | 99.7% | -170.6% |
| EPS (diluted) | $-0.02 | $-0.80 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $334.0M | ||
| Q4 25 | $180.9M | $334.0M | ||
| Q3 25 | $177.8M | $382.0M | ||
| Q2 25 | $175.0M | $397.0M | ||
| Q1 25 | $167.5M | $316.0M | ||
| Q4 24 | $179.6M | $336.0M | ||
| Q3 24 | $170.4M | $396.0M | ||
| Q2 24 | $171.7M | $367.0M |
| Q1 26 | — | $-60.0M | ||
| Q4 25 | $-1.3M | $-60.0M | ||
| Q3 25 | $-1.4M | $105.0M | ||
| Q2 25 | $-76.8M | $87.0M | ||
| Q1 25 | $6.6M | $61.0M | ||
| Q4 24 | $-397.3M | $85.0M | ||
| Q3 24 | $4.3M | $102.0M | ||
| Q2 24 | $1.8M | $86.0M |
| Q1 26 | — | — | ||
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | -11.4% | ||
| Q3 25 | 0.1% | 46.6% | ||
| Q2 25 | -42.6% | 37.8% | ||
| Q1 25 | 6.1% | 35.4% | ||
| Q4 24 | -233.0% | 38.4% | ||
| Q3 24 | 7.0% | 43.2% | ||
| Q2 24 | 3.7% | 39.5% |
| Q1 26 | — | -18.0% | ||
| Q4 25 | -0.7% | -18.0% | ||
| Q3 25 | -0.8% | 27.5% | ||
| Q2 25 | -43.9% | 21.9% | ||
| Q1 25 | 3.9% | 19.3% | ||
| Q4 24 | -221.2% | 25.3% | ||
| Q3 24 | 2.5% | 25.8% | ||
| Q2 24 | 1.0% | 23.4% |
| Q1 26 | — | $-0.80 | ||
| Q4 25 | $-0.02 | $-0.77 | ||
| Q3 25 | $-0.03 | $1.36 | ||
| Q2 25 | $-1.66 | $1.13 | ||
| Q1 25 | $0.14 | $0.78 | ||
| Q4 24 | $-8.64 | $1.06 | ||
| Q3 24 | $0.09 | $1.29 | ||
| Q2 24 | $0.04 | $1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $64.0M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $468.0M |
| Total Assets | $1.1B | $4.2B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $64.0M | ||
| Q4 25 | $89.8M | $64.0M | ||
| Q3 25 | $70.5M | $70.0M | ||
| Q2 25 | $90.3M | $50.0M | ||
| Q1 25 | $97.0M | $48.0M | ||
| Q4 24 | $107.7M | $103.0M | ||
| Q3 24 | $89.0M | $72.0M | ||
| Q2 24 | $92.2M | $70.0M |
| Q1 26 | — | — | ||
| Q4 25 | $90.3M | $2.5B | ||
| Q3 25 | $93.4M | $2.6B | ||
| Q2 25 | $95.7M | $2.5B | ||
| Q1 25 | $98.0M | $2.5B | ||
| Q4 24 | $125.3M | $2.4B | ||
| Q3 24 | $152.6M | $2.4B | ||
| Q2 24 | $164.9M | $2.4B |
| Q1 26 | — | $468.0M | ||
| Q4 25 | $778.2M | $468.0M | ||
| Q3 25 | $778.0M | $583.0M | ||
| Q2 25 | $776.3M | $570.0M | ||
| Q1 25 | $839.4M | $579.0M | ||
| Q4 24 | $828.5M | $650.0M | ||
| Q3 24 | $1.2B | $583.0M | ||
| Q2 24 | $1.2B | $623.0M |
| Q1 26 | — | $4.2B | ||
| Q4 25 | $1.1B | $4.2B | ||
| Q3 25 | $1.1B | $4.3B | ||
| Q2 25 | $1.0B | $4.3B | ||
| Q1 25 | $1.1B | $4.2B | ||
| Q4 24 | $1.2B | $4.2B | ||
| Q3 24 | $1.7B | $4.2B | ||
| Q2 24 | $1.7B | $4.2B |
| Q1 26 | — | — | ||
| Q4 25 | 0.12× | 5.37× | ||
| Q3 25 | 0.12× | 4.43× | ||
| Q2 25 | 0.12× | 4.44× | ||
| Q1 25 | 0.12× | 4.29× | ||
| Q4 24 | 0.15× | 3.72× | ||
| Q3 24 | 0.12× | 4.19× | ||
| Q2 24 | 0.13× | 3.83× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $367.0M |
| Free Cash FlowOCF − Capex | $21.3M | $168.0M |
| FCF MarginFCF / Revenue | 11.8% | 50.3% |
| Capex IntensityCapex / Revenue | 3.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $437.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $367.0M | ||
| Q4 25 | $28.2M | $152.0M | ||
| Q3 25 | $14.0M | $86.0M | ||
| Q2 25 | $6.8M | $70.0M | ||
| Q1 25 | $25.7M | $59.0M | ||
| Q4 24 | $57.9M | $134.0M | ||
| Q3 24 | $23.0M | $79.0M | ||
| Q2 24 | $27.8M | $1.0M |
| Q1 26 | — | $168.0M | ||
| Q4 25 | $21.3M | $136.0M | ||
| Q3 25 | $7.0M | $75.0M | ||
| Q2 25 | $-4.2M | $58.0M | ||
| Q1 25 | $19.0M | $52.0M | ||
| Q4 24 | $53.1M | $109.0M | ||
| Q3 24 | $20.0M | $71.0M | ||
| Q2 24 | $21.9M | $-6.0M |
| Q1 26 | — | 50.3% | ||
| Q4 25 | 11.8% | 40.7% | ||
| Q3 25 | 3.9% | 19.6% | ||
| Q2 25 | -2.4% | 14.6% | ||
| Q1 25 | 11.3% | 16.5% | ||
| Q4 24 | 29.6% | 32.4% | ||
| Q3 24 | 11.7% | 17.9% | ||
| Q2 24 | 12.8% | -1.6% |
| Q1 26 | — | — | ||
| Q4 25 | 3.8% | 4.8% | ||
| Q3 25 | 3.9% | 2.9% | ||
| Q2 25 | 6.3% | 3.0% | ||
| Q1 25 | 4.0% | 2.2% | ||
| Q4 24 | 2.7% | 7.4% | ||
| Q3 24 | 1.8% | 2.0% | ||
| Q2 24 | 3.4% | 1.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.82× | ||
| Q2 25 | — | 0.80× | ||
| Q1 25 | 3.89× | 0.97× | ||
| Q4 24 | — | 1.58× | ||
| Q3 24 | 5.35× | 0.77× | ||
| Q2 24 | 15.44× | 0.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
WH
| Fee-related and other revenues | $334.0M | 100% |
| Management and other fees | $2.0M | 1% |
